News for UroGen Pharma Ltd. (0XOD.L)

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Phar

LOS ANGELES, June 06, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shar

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Phar

Leading securities law firm [url="]Bleichmar Fonti & Auld LLP[/url] announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certa

As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. The following biotech companies are awaiting potential approvals in June 2025.

On May 23, 2025, Guggenheim's analyst Michael Schmidt released an update regarding the stock of UroGen Pharma (URGN). The analyst maintained a

Guggenheim has revised its price target for UroGen Pharma (URGN), bringing it down to $15 from the previous $40 while maintaining a Buy rating on the stock. The

On May 22, 2025, leading investment bank Goldman Sachs, through its analyst Paul Choi, announced a significant adjustment in its outlook for UroGen Pharma (URGN

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (”œUroGen” or the ”œCompanyâ

H.C. Wainwright has revised their rating for UroGen Pharma (URGN), moving it from "Buy" to "Neutral." The downgrade follows a negative vote from an FDA panel co

UroGen Pharma's stock plunged 47% after an FDA panel's tight 4-5 vote against its bladder cancer treatment. Analysts forecast significant upside potenti

UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and special

UroGen Pharma (URGN) recently experienced a narrow vote by the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration. The committee

PR NewswireNEW YORK, May 20, 2025 NEW YORK, May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd.

Law Offices of Howard G. Smith announces an investigation on behalf of UroGen Pharma Ltd. (”œUroGen” or the ”œCompany”) (NASDAQ: [url="]URGN[/url]) inves

U.S. stocks were mostly higher, with the Dow Jones index gaining around 200 points on Monday. Shares of CEMEX, S.A.B. de C.V. CX rose sharply during Monday's s...

UroGen Pharma (URGN) has released new findings from the OPTIMA II Phase 2b study concerning its UGN-102 intravesical solution. The study reveals that UGN-102 de

UroGen Pharma (URGN) has released promising results from its Phase 3 ENVISION trial concerning UGN-102, an investigational therapy for recurrent low-grade inter

UroGen Pharma (URGN) has released promising safety outcomes from its Phase 1 study of UGN-301, an experimental treatment for recurrent non-muscle invasive bladd